• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Morbidity and Mortality Weekly Report >Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut December 2020–February 2021
【2h】

Effectiveness of the Pfizer-BioNTech COVID-19 Vaccine Among Residents of Two Skilled Nursing Facilities Experiencing COVID-19 Outbreaks — Connecticut December 2020–February 2021

机译：PFizer-Biontech Covid-19患者在经历Covid-19爆发的居民居民中疫苗的有效性 - 康涅狄格州12月2020年2月2021年

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Residents of long-term care facilities (LTCFs), particularly those in skilled nursing facilities (SNFs), have experienced disproportionately high levels of COVID-19–associated morbidity and mortality and were prioritized for early COVID-19 vaccination (1,2). However, this group was not included in COVID-19 vaccine clinical trials, and limited postauthorization vaccine effectiveness (VE) data are available for this critical population (3). It is not known how well COVID-19 vaccines protect SNF residents, who typically are more medically frail, are older, and have more underlying medical conditions than the general population (1). In addition, immunogenicity of the Pfizer-BioNTech vaccine was found to be lower in adults aged 65–85 years than in younger adults (4). Through the CDC Pharmacy Partnership for Long-Term Care Program, SNF residents and staff members in Connecticut began receiving the Pfizer-BioNTech COVID-19 vaccine on December 18, 2020 (5). Administration of the vaccine was conducted during several on-site pharmacy clinics. In late January 2021, the Connecticut Department of Public Health (CT DPH) identified two SNFs experiencing COVID-19 outbreaks among residents and staff members that occurred after each facility’s first vaccination clinic. CT DPH, in partnership with CDC, performed electronic chart review in these facilities to obtain information on resident vaccination status and infection with SARS-CoV-2, the virus that causes COVID-19. Partial vaccination, defined as the period from >14 days after the first dose through 7 days after the second dose, had an estimated effectiveness of 63% (95% confidence interval [CI] = 33%–79%) against SARS-CoV-2 infection (regardless of symptoms) among residents within these SNFs. This is similar to estimated effectiveness for a single dose of the Pfizer-BioNTech COVID-19 vaccine in adults across a range of age groups in noncongregate settings (6) and suggests that to optimize vaccine impact among this population, high coverage with the complete 2-dose series should be recommended for SNF residents and staff members.
机译：长期护理设施（LTCF）的居民，特别是那些熟练的护理设施（SNF）的居民，经历了不成比例的Covid-19相关的发病率和死亡率，并且优先考虑早期Covid-19疫苗接种（1,2）。然而，该组不包括在Covid-19疫苗临床试验中，并且有限的后授权疫苗有效性（VE）数据可用于这种关键人口（3）。尚不讨论Covid-19疫苗如何保护通常是多级医疗勒索的SNF居民，年龄较大，并且具有比一般人群更大的医疗条件（1）。此外，发现辉瑞疫情的疫苗疫苗的免疫原性比在65-85岁年龄较小的成人（4）中较低。通过CDC药房合作，为长期护理计划，SNF居民和康涅狄格州的工作人员于2020年12月18日开始收到PFizer-Biontech Covid-19疫苗。在几个现场药房诊所进行疫苗的施用。 2021年下旬，康涅狄格州公共卫生部（CT DPH）确定了两个SNF，在每个设施的第一个接种诊所后发生的居民和工作人员中经历了Covid-19爆发。与CDC合作的CT DPH在这些设施中进行了电子图表审查，以获取有关常规疫苗接种状态和患有SARS-COV-2的感染的信息，导致Covid-19的病毒。部分疫苗接种，定义为第二剂量后7天后的> 14天的时间，估计有效性为63％（95％置信区间[CI] = 33％-79％）对抗SARS-COV- 2个感染（无论症状如何）这些SNF中的居民之间。这类似于在非共同设置（6）中的一系列年龄组中成人中单剂量普及的辉瑞 - Biontech Covid-19疫苗的估计有效性，并表明可以优化这群人群的疫苗影响，完整的2 -Dose系列应建议为SNF居民和工作人员。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号